Collegium Pharmaceutical (COLL) Short term Debt (2014 - 2026)

Collegium Pharmaceutical's Short term Debt history runs 13 years deep, the most recent figure standing at $32.6 million for Q1 2026.

• On a quarterly basis, Short term Debt rose 32.81% year-over-year to $32.6 million in Q1 2026; TTM through Mar 2026 was $32.6 million, a 32.81% increase from a year earlier, with the FY2025 full-year figure at $29.0 million, down 55.1% from the prior year.
• Short term Debt climbed to $32.6 million in Q1 2026 per COLL's latest filing, from $29.0 million in the prior quarter.
• Across five years, Short term Debt topped out at $183.3 million in Q1 2023 and bottomed at $19000.0 in Q3 2025.
• The 5-year median for Short term Debt is $120.8 million (2022), against an average of $112.1 million.
• Across the five-year window, Short term Debt jumped 236.07% in 2022 and tumbled 99.97% in 2025, its largest moves.
• Year by year, Short term Debt stood at $162.5 million in 2022, then advanced by 12.82% to $183.3 million in 2023, then plunged by 64.77% to $64.6 million in 2024, then plunged by 55.1% to $29.0 million in 2025, then rose by 12.5% to $32.6 million in 2026.
• Per Business Quant, the three latest COLL Short term Debt figures stand at $32.6 million (Q1 2026), $29.0 million (Q4 2025), and $19000.0 (Q3 2025).